Two years after starting the treatment, 68% of were still living without their cancer progressing compared to 57% of people who received just chemoradiotherapy, an NHS spokesperson said.
About 550 people will be eligible for the treatment over the next two years, the NHS estimates.
Around 3,300 people are diagnosed with cervical cancer each year, according to Cancer Research UK.
Lyndsey Ambler, from the charity, said: “Adding immunotherapy to standard cancer treatment could improve people’s chances of survival, so it’s encouraging that pembrolizumab is being made available for some people with locally advanced cervical cancer through the Cancer Drugs Fund.
“This decision may also allow some patients to access the drug earlier in their treatment than previously.”
Follow BBC Surrey on Facebook, external, on X, external, and on Instagram, external and listen to BBC Radio Surrey on Sounds. Send your story ideas to southeasttoday@bbc.co.uk, external or WhatsApp us on 08081 002250.
